MTNB Insider Trading Activity and SEC Form 4 Filings
MTNB insider trading summary
No open-market insider purchases or sales of Matinas BioPharma Holdings, Inc. (MTNB) have been reported on SEC Form 4 in the past 12 months.
Latest MTNB insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 21, 2020 | Adam K Stern | Director | Buy | $17K (20,000 @ $0.83) |
| May 14, 2020 | Patrick G Lepore | Director | Buy | $73K (100,000 @ $0.73) |
| Mar 17, 2020 | Jerome D Jabbour | President and CEO | Buy | $7K (10,000 @ $0.65) |
| Mar 17, 2020 | Adam K Stern | Director | Buy | $7K (10,000 @ $0.65) |
| Nov 25, 2019 | Keith A Kucinski | Chief Financial Officer | Buy | $71K (58,000 @ $1.23) |
| Nov 22, 2019 | Keith A Kucinski | Chief Financial Officer | Buy | $44K (36,500 @ $1.20) |
| Nov 15, 2019 | Patrick G Lepore | Director | Buy | $106K (100,000 @ $1.06) |
| Aug 20, 2019 | Eric J Ende | Director | Buy | $13K (20,000 @ $0.66) |
| Aug 19, 2019 | Eric J Ende | Director | Buy | $14K (20,000 @ $0.68) |
| Aug 19, 2019 | Adam K Stern | Director | Buy | $7K (10,400 @ $0.70) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.